BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37643636)

  • 41. Lynch syndrome caused by a novel deletion of the promoter and exons 1-13 of MLH1 gene.
    Huang J; Stinnett V; Jiang L; Chen S; Rodriguez F; Gocke CD; Zou YS
    Cancer Genet; 2022 Apr; 262-263():91-94. PubMed ID: 35149321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular tumor testing in patients with Lynch-like syndrome reveals a de novo mosaic variant of a mismatch repair gene transmitted to offspring.
    Guillerm E; Svrcek M; Bardier-Dupas A; Basset N; Coulet F; Colas C
    Eur J Hum Genet; 2020 Nov; 28(11):1624-1628. PubMed ID: 32678338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
    Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
    Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of Mismatch Repair-Deficient Colon Cancer in Relation to Mismatch Repair Protein Loss, Hypermethylation Silencing, and Constitutional and Biallelic Somatic Mismatch Repair Gene Pathogenic Variants.
    Keshinro A; Ganesh K; Vanderbilt C; Firat C; Kim JK; Chen CT; Yaeger R; Segal NH; Gonen M; Shia J; Stadler ZK; Weiser MR
    Dis Colon Rectum; 2023 Apr; 66(4):549-558. PubMed ID: 35724254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.
    Jansen AM; Geilenkirchen MA; van Wezel T; Jagmohan-Changur SC; Ruano D; van der Klift HM; van den Akker BE; Laros JF; van Galen M; Wagner A; Letteboer TG; Gómez-García EB; Tops CM; Vasen HF; Devilee P; Hes FJ; Morreau H; Wijnen JT
    PLoS One; 2016; 11(6):e0157381. PubMed ID: 27300758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
    N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional Characterization of a Missense Variant of
    Zaib T; Zhang C; Saleem K; Xu L; Qin Q; Wang Y; Ji W; Khan H; Yu H; Zhu S; Gao W; Huang Y; Jia X; Wu J; Song H; Zhang Y; Sun W; Fu S
    Dis Markers; 2020; 2020():8360841. PubMed ID: 32076465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
    Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
    Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer.
    Bapat BV; Madlensky L; Temple LK; Hiruki T; Redston M; Baron DL; Xia L; Marcus VA; Soravia C; Mitri A; Shen W; Gryfe R; Berk T; Chodirker BN; Cohen Z; Gallinger S
    Hum Genet; 1999 Feb; 104(2):167-76. PubMed ID: 10190329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel deletion in the splice donor site of MLH1 exon 6 in a Japanese colon cancer patient with Lynch syndrome.
    Yamaguchi J; Sato Y; Kita M; Nomura S; Yamamoto N; Kato Y; Ishikawa Y; Arai M
    Jpn J Clin Oncol; 2015 Oct; 45(10):993-7. PubMed ID: 26185136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.
    Hesson LB; Packham D; Kwok CT; Nunez AC; Ng B; Schmidt C; Fields M; Wong JW; Sloane MA; Ward RL
    Hum Mutat; 2015 Jun; 36(6):622-30. PubMed ID: 25762362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
    Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
    Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression.
    Cabreira V; Pinto C; Pinheiro M; Lopes P; Peixoto A; Santos C; Veiga I; Rocha P; Pinto P; Henrique R; Teixeira MR
    Fam Cancer; 2017 Jan; 16(1):73-81. PubMed ID: 27581132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
    Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
    Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
    Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
    Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
    Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
    J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.